BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
| Revenue (TTM) | $5.34B |
| Gross Profit (TTM) | $4.67B |
| EBITDA | $578.82M |
| Operating Margin | 12.30% |
| Return on Equity | 7.46% |
| Return on Assets | 3.96% |
| Revenue/Share (TTM) | $48.99 |
| Book Value | $39.34 |
| Price-to-Book | 7.52 |
| Price-to-Sales (TTM) | 6.11 |
| EV/Revenue | 5.61 |
| EV/EBITDA | 48.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 32.80% |
| Shares Outstanding | $102.28M |
| Float | $1.01B |
| % Insiders | 17.29% |
| % Institutions | 32.08% |
Volatility is currently contracting